

Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?

Atsushi Tanaka^a Joachim C. Mertens^b

^aDepartment of Medicine, Teikyo University School of Medicine, Tokyo, Japan; ^bUniversity Hospital Zurich, Zurich, Switzerland

Key Words

Ulcerative colitis · Primary sclerosing cholangitis

Abstract

Background: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin and an important hepatobiliary complication of inflammatory bowel diseases (IBD), especially ulcerative colitis (UC). When further differentiated, about 3–8% of UC patients suffer from PSC, whereas among Crohn's disease patients the reported prevalence of PSC is probably between 1 and 3.5%. Although it was reported from Japan that the frequency of PSC in UC was only 34%, the same registry data indicated that the prevalence was up to 57% among young patients with PSC even in Japan, which is comparable to the 60–80% in Europe and the US. Additionally, the clinical features of UC in patients with PSC are different from those in patients without PSC, for instance, rectal sparing and right-sided dominance. **Summary:** The strong link between atypical IBD and PSC suggests that

the pathogenesis of PSC involves pathology of the gut, including abnormal gut microbiota and aberrant activation of mucosal lymphocytes. These seem to be different in UC PSC as compared to the pathology of typical UC. **Key Messages:** The key to solving the question 'Is there a difference between East and West?' are genetic studies, genome-wide association studies of PSC in particular, which have already been performed in the West and are strongly warranted in the East.

© 2016 S. Karger AG, Basel

Background West

In Europe, especially Northern Europe, about 70–80% of patients with primary sclerosing cholangitis (PSC) are also diagnosed with inflammatory bowel disease (IBD). This is primarily ulcerative colitis (UC), less frequently Crohn's disease (CD) [1]. Conversely, abnormalities of the hepatobiliary systems are found in up to 30% of IBD patients [2].

A.T. and J.C.M. contributed equally to this work.

KARGER

E-Mail karger@karger.com
www.karger.com/iid

© 2016 S. Karger AG, Basel
2296–9403/16/0011–0009\$39.50/0

Prof. Atsushi Tanaka, MD
Department of Medicine, Teikyo University School of Medicine
2-11-1, Kaga, Itabashi-ku
Tokyo 173-8605 (Japan)
E-Mail a-tanaka@med.teikyo-u.ac.jp

Joachim C. Mertens, MD
University Hospital Zurich
Rämistrasse 100
CH-8091 Zurich (Switzerland)
E-Mail Joachim.Mertens@usz.ch

Of the liver diseases specifically associated with IBD, PSC is the most common, affecting up to 5% of all IBD patients depending on the geographic region [3]. When further differentiated, about 3–8% of UC patients suffer from PSC [4, 5], while in CD patients the reported prevalence of PSC is probably between 1 and 3.5% [6]. PSC has a clear male predominance with a ratio of 2:1.

Prior to the diagnosis of PSC in a patient with elevated serum markers of cholestasis (alkaline phosphatase and γ -glutamyltransferase), a possible secondary sclerosing cholangitis caused, for example, by infection, ischemia, IgG4-related cholangiopathy, or autoimmune hepatitis needs to be excluded. While PSC may present with symptoms like fever, night sweats, and pruritus, it is important to remember that IBD patients are frequently asymptomatic with regard to their liver disease, and physicians treating IBD patients need to actively investigate for possible associated hepatobiliary conditions [7]. The diagnostic gold standard for PSC remains magnetic resonance cholangiography (MRC), with typical ‘string-of-pearls’ imaging features of bile duct changes with multifocal strictures and segmental dilatations. MRC findings may be complemented by histology from liver biopsy if imaging is inconclusive. Histologically, PSC can be differentiated by several staging systems. The Ludwig staging system applies 4 stages to describe the histological features of PSC: cholangitis and portal inflammation (stage I), periportal inflammation or fibrosis (stage II), septal fibrosis and/or bridging necrosis (stage III), and biliary cirrhosis (stage IV). The applicability and prognostic value of the histological scoring was just recently confirmed by de Vries et al. [8]. Patients that present with clinical, biochemical, and histological findings indicating PSC but show a normal cholangiogram in MRC are classified as having small-duct PSC [9]. Small-duct PSC seems to have differing HLA associations, depending on whether it occurs in the context of IBD or not. While small-duct PSC in IBD is associated with HLA-B*08 and thus seems to be an early or mild form of large-duct PSC, small-duct PSC without IBD displays a different association with HLA-DRB1*13:01 and may represent a different entity of inflammatory cholangitis. In general, small-duct PSC may have a better prognosis than large-duct PSC [10].

Currently there is no therapy for PSC available that has been shown to alter the course of the disease. Guidelines in Europe and the US differ regarding the use of ursodeoxycholic acid (UDCA), which has been shown to improve laboratory values and histology in PSC pa-

tients when given at doses not higher than 15 mg/kg/day [11, 12]. Unfortunately, UDCA has no proven benefit for transplant-free and overall survival. 24-norUrsodeoxycholic acid is a novel, modified derivative of UDCA currently in clinical trial after promising results in a PSC animal model [13].

Focusing on the characteristics of UC associated with PSC, it was noted that the course of the IBD is more often benign, with mild-to-quiescent clinical symptoms and possibly even normal endoscopic appearance that might result in underdiagnosis of UC in PSC patients [14]. Yet, pancolitis and rectal sparing are described more frequently, that is, in about 65 and 30%, respectively, of UC PSC patients, compared to 50 and 10% of UC patients without PSC. Backwash ileitis may occur slightly more often in UC PSC (17 vs. 12%), but the data are controversial [4, 15, 16]. Possibly due to the milder and sometimes subclinical course of the IBD despite pancolitis, the risk of colorectal cancer (CRC) seems to be substantially higher in UC PSC. Alternative theories implicate impaired hepatic excretion of bile acids with subsequent accumulation of potentially mutagenic secondary bile acids in the colon [17, 18]. The fact that CRC in UC PSC develops more frequently in the right hemicolon with the highest concentration of secondary bile acids could support this proposed pathogenetic mechanism, as could the potential protective effect of UDCA [16, 19]. CRC in UC PSC seems to develop earlier in the course of the disease, with a mean interval from IBD diagnosis to CRC of 12–20 years compared to 17–44 years in non-PSC IBD, but a possible lead time bias due to earlier screening in UC PSC is being debated.

The striking association of PSC with UC has sparked numerous investigations into the underlying pathogenetic mechanisms, giving rise to several theories that link the two diseases to each other. While both are considered an immune-mediated condition, PSC lacks features of classic autoimmune diseases, beginning with its male predominance and the lack of response to any immunosuppressive therapy. Moreover, no disease-specific autoantibody has been identified for PSC [20].

There is mounting evidence that genetic susceptibility plays an important role in the development of both diseases and may constitute a strong link between them. There is an up to 40-fold increased risk of PSC in 1st-degree relatives when compared to the general population, supporting the concept of genetic susceptibility. Moreover, strong associations with HLA genes have been described earlier. In a recent genome-wide asso-

ciation study (GWAS), a total of 16 strong susceptibility loci for PSC were identified, 12 of which were found outside the HLA region. There was a genetic overlap with known IBD susceptibility loci in only half of the identified PSC risk loci, indicating a similar but distinct genetic architecture. Likewise, 50% of the PSC loci overlap with susceptibility loci for other autoimmune diseases. For the PSC-IBD-overlapping loci there was a greater similarity between PSC and UC than between PSC and CD, indicating a greater genetic similarity between PSC and UC. This is consistent with the much more frequent clinical association [21]. Importantly, the newly identified genetic risk factors account for no more than 10% of the estimated overall PSC susceptibility, again raising the important question of environmental factors for the PSC pathogenesis.

In addition to the firmly established genetic association between PSC and IBD there are the long-standing hypotheses of 'leaky gut' and 'toxic bile', which may likewise contribute to the close relationship between PSC and UC. The chronically inflamed and disturbed intestinal barrier in the setting of UC may facilitate a 'leakage' of bacterial components into the portal circulation and subsequent portal inflammation. The hepatic overload with products from the intestinal microbiota may also cause 'aberrant lymphocyte homing' of gut-restricted T cells into the liver [22, 23]. This immunological mechanism of liver injury may be complemented by an altered bile composition in PSC, leading to more toxic bile with a resulting local injury to bile duct epithelia.

Key Messages West

PSC and UC are strongly associated in Europe and the US. Recent GWAS show a substantial genetic overlap while confirming distinct disease entities. The clinical course of UC with PSC is often oligosymptomatic compared to UC without PSC. Nonetheless, patients with UC PSC exhibit an increased risk for CRC. There currently is no effective therapy to alter the outcome of PSC.

Conclusions West

PSC with UC likely represents a distinct disease variant that requires special clinical surveillance. Further research into the gut-liver axis is needed to better understand and potentially treat this disease complex.

Background East

PSC is a chronic cholestatic liver disease of unknown origin, characterized by the progressive destruction of bile ducts caused by diffuse inflammation and fibrosis, which eventually leads to liver cirrhosis [24]. PSC is believed to be a rare disease in Asia compared to Europe and North America. In fact, population-based epidemiological data on PSC are lacking in Asia; since 1996 there have been several small case series from India [25], Singapore [26], Korea [27], and Iran [28], each of them enrolling 10–20 patients with PSC. In the study from India [25], 18 patients were presented, and their clinical profiles including age (mean age 39.0 years) and male predominance were comparable to those in the West. IBD were found in 50% of the patients. The outcomes were poor; 4 patients died during the 20.1-month follow-up period. The study from Singapore [26] had enrolled 10 cases with PSC (mean age 50.9 years), confirming the male predominance; however, the outcome was better, with only 1 death during 6.6 years of follow-up. The only epidemiological data available in Asia are data from our group presenting the prevalence of PSC in Japan, as reported in 2014 [29]. According to this work and other previously reported data from the West, incidence and prevalence rates of PSC are summarized in table 1. Except in the study conducted in 1994, the prevalence of PSC was around 5–16 per 100,000 inhabitants in the West, compared to less than 1.0 in Japan. Although the reason for this difference is unclear, genetic factors clearly play a crucial role.

In Japan, we performed questionnaire-based, nationwide surveys for PSC in 2012 and 2015. According to this study [29], several characteristic features of Japanese PSC patients, which had been scarcely demonstrated before by epidemiological studies from other countries, were demonstrated. First, there were 2 peaks in age distribution at diagnosis, that is, in the 3rd and 7th decades of life (fig. 1). Most of the previous epidemiological studies from North America and Europe indicated a single age group for the highest risk of developing PSC [30–33], with the exception of one study in Canada, which suggested two age groups (18–35 and >65 years) as being at higher risk, similar to what has been found in Japanese studies [34]. Second, the prevalence of IBD among PSC patients appeared to be low compared to that in Europe and North America, as described below. The estimated median survival was 13.1 years, and 5-year survival of all patients was 74.5%. Multivariate analysis demonstrated that age (OR = 1.73, 1.09–2.75, $p = 0.0206$) and total bilirubin (OR = 2.32,




Fig. 1. Age distribution at presentation of patients with PSC in Japan.




Fig. 2. Prevalence of IBD in patients with PSC in Japan. CF = Colono-fiberscope.

Table 1. Incidence and prevalence of PSC

First author [Ref.], year	Country	Study period	Method of case ascertainment	Cases, n	Incidence ^a (95% CI)	Prevalence ^a (95% CI)
Escorsell [36], 1994	Spain	1984–1988	Questionnaires	43	0.07	0.22
Berdal [37], 1998	Norway	1985–1994	ICD codes	12	0.7	5.6
Boberg [38], 1998	Norway	1986–1995	Prospective cohort	17	1.3 (0.8–2.1)	8.5 (2.8–14.2)
Bambha [39], 2003	USA	1976–2000	Medical record linkage system	22	0.9	13.6
Card [40], 2008	UK	1987–2002	General Practice Research Database	149	0.41 (0.34–0.48)	3.85 (3.04–4.80)
Kingham [41], 2004	UK	1984–2003	Prospective cohort	46	0.91	12.7
Lindkvist [42], 2010	Sweden	1992–2005	ICD codes	199	1.22	16.2
Kaplan [43], 2007	Canada	2000–2005	Retrospective cohort	49	0.92	N/A
Boonstra [44], 2013	The Netherlands	2000–2007	Retrospective cohort	519	0.5	6.0
Tanaka [45], 2008	Japan	2007	Questionnaires	415	N/A	0.95 (0.61–1.29)

N/A = Not available. ^a Per 100,000 inhabitants.

1.47–3.66, $p = 0.0003$) were independent risk factors for the outcome of PSC in Japan [35].

PSC is an important hepatobiliary complication of UC. According to the reports from the West, PSC is observed as a comorbidity in 2.9–7.6% of patients with UC [7]. In the East, case series from Iran [28] and South Korea [27] demonstrated that the frequency of PSC among UC cases was 4.3% (19/447) and 1.1% (21/1,849), respectively, suggesting a comparable prevalence of PSC among patients with UC. Regarding patients with PSC, the prevalence of UC was striking: up to 80% of PSC patients have concomitant IBD. However, there appears to be a considerable geographical variation. In the study from Singapore [26],

IBD was found in 20% of patients with PSC, although only 10 cases were included. In our nationwide study in Japan, however, the prevalence of IBD as a comorbidity was low in Japanese PSC patients [29]. The presence of IBD was restricted to only 34% (68/197) of PSC patients. However, there are considerable differences in the prevalence of IBD between young and elderly patients. Their mean age was 48.1 years, and when comparing patients younger than 48.1 years with elderly patients, the prevalence of IBD was 12% in the elderly and 57% in the young PSC patients, the latter rate being comparable to the prevalence rates in Europe and the US (fig. 2). Taken together, the phenotype of PSC in the younger generation is similar to that in the

West, while PSC in the elderly is a somewhat different disease and might not be 'primary' but 'secondary' sclerosing cholangitis.

It is also of note that, from Japanese experience, the clinical features of UC in patients with PSC are different from those in patients without PSC. It is known that several unique features were noted, such as rectal sparing and right-sided dominance, in UC patients with PSC. In addition, nonspecific or unclassified colitis is frequently found in patients with PSC. Interestingly, this atypical UC or IBD is also reported in a retrospective cohort study of IBD patients in Korea [27], as well as in North America and European countries. Thus, the atypical presentation of IBD in PSC patients appears to be a general phenomenon worldwide. Furthermore, the strong link between atypical IBD and PSC suggests that the pathology of PSC clearly involves pathology of the gut, including abnormal gut microbiota and aberrant activation of mucosal lymphocytes, which seems to be different from the pathology of typical IBD or UC.

Obviously, the key to solving the question 'Is there a difference between East and West?' are genetic studies, GWAS of PSC in particular. While GWAS in patients with PSC were performed in the West and they indicated several susceptibility loci contributing to the development of PSC overlapping with those for IBD and other autoimmune diseases, no GWAS have been performed in the East. On another cholestatic liver disease, primary biliary cholangitis, GWAS have been performed both in the East and the West, demonstrating the involvement of similar pathways in the pathogenesis of primary biliary cholangitis, even though the susceptibility genes themselves were different, but there seemed to be no difference in genetic background between East and West. In Japan, GWAS using both young and elderly PSC patients are needed, and results should be analyzed and compared between younger PSC (with high complication rates of IBD)

and elderly PSC patients (with low rates of IBD). Clinical experience suggests that the susceptibility loci in young PSC patients are similar to those observed in the West and overlapping with those in IBD or autoimmune diseases as well, while the susceptibility loci in the elderly are quite different or even undetectable.

Key Messages East

Japanese epidemiological data indicate that the prevalence of UC in patients with PSC appears to be low. However, in younger patients with PSC the prevalence of UC is 50–60%, comparable to that in Europe and the US. It is reasonable to assume that in the younger generation, the phenotype of PSC is similar to that in the West. It is also of note that the clinical features of UC in patients with PSC are different from those in patients without PSC, for instance, rectal sparing and right-sided dominance and nonspecific or unclassified colitis.

Conclusions East

Genetic studies – GWAS for PSC in particular – are strongly warranted to solve the question whether there is a difference between PSC in the West and PSC in the East. Clinical experience suggests that the susceptibility loci in young PSC patients are similar to those observed in the West and overlapping with those in IBD or autoimmune diseases as well, while the susceptibility loci in the elderly are quite different or even undetectable.

Disclosure Statement

The authors have nothing to disclose.

References

- 1 Karlsen TH, Boberg KM: Update on primary sclerosing cholangitis. *J Hepatol* 2013;59: 571–582.
- 2 Mendes FD, et al: Abnormal hepatic biochemistries in patients with inflammatory bowel disease. *Am J Gastroenterol* 2007;102: 344–350.
- 3 Fausa O, Schrumpf E, Elgjo K: Relationship of inflammatory bowel disease and primary sclerosing cholangitis. *Semin Liver Dis* 1991; 11:31–39.
- 4 Olsson R, et al: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. *Gastroenterology* 1991;100:1319–1323.
- 5 Saich R, Chapman R: Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. *World J Gastroenterol* 2008;14:331–337.
- 6 Rasmussen HH, et al: Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. *Scand J Gastroenterol* 1997;32:604–610.
- 7 Kummern M, Schrumpf E, Boberg KM: Liver abnormalities in bowel diseases. *Best Pract Res Clin Gastroenterol* 2013;27:531–542.
- 8 de Vries EM, et al: Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. *J Hepatol* 2015; 63:1212–1219.
- 9 European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol* 2009;51:237–267.

- 10 Naess S, et al: Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. *Liver Int* 2014;34:1488–1495.
- 11 Beuers U, et al: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. *Hepatology* 1992;16:707–714.
- 12 Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *N Engl J Med* 1997;336:691–695.
- 13 Fickert P, et al: 24-*nor*Ursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in *Mdr2 (Abcb4)* knockout mice. *Gastroenterology* 2006;130:465–481.
- 14 Jørgensen KK, et al: Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. *Inflamm Bowel Dis* 2012;18:536–545.
- 15 Sinakos E, et al: Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. *Inflamm Bowel Dis* 2013;19:1004–1009.
- 16 de Vries AB, et al: Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. *World J Gastroenterol* 2015;21:1956–1971.
- 17 Torres J, et al: Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. *Aliment Pharmacol Ther* 2011;34:497–508.
- 18 Bernstein H, et al: Bile acids as carcinogens in human gastrointestinal cancers. *Mutat Res* 2005;589:47–65.
- 19 de Valle MB, Björnsson E, Lindkvist B: Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. *Liver Int* 2012;32:441–448.
- 20 Kronen E, et al: Evolving concepts in primary sclerosing cholangitis. *Liver Int* 2012;32:352–369.
- 21 Liu JZ, et al: Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nat Genet* 2013;45:670–675.
- 22 Adams DH, Eksteen B: Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. *Nat Rev Immunol* 2006;6:244–251.
- 23 Weismüller TJ, et al: The challenges in primary sclerosing cholangitis – aetiopathogenesis, autoimmunity, management and malignancy. *J Hepatol* 2008;48(suppl 1):S38–S57.
- 24 Hirschfield GM, et al: Primary sclerosing cholangitis. *Lancet* 2013;382:1587–1599.
- 25 Kochhar R, et al: Primary sclerosing cholangitis: an experience from India. *J Gastroenterol Hepatol* 1996;11:429–433.
- 26 Ang TL, et al: Clinical profile of primary sclerosing cholangitis in Singapore. *J Gastroenterol Hepatol* 2002;17:908–913.
- 27 Ye BD, et al: Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea. *Inflamm Bowel Dis* 2011;17:1901–1906.
- 28 Khosravi Khorashad A, et al: Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran. *Gastroenterol Hepatol Bed Bench* 2015;8:200–206.
- 29 Tanaka A, et al: Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. *J Hepatobiliary Pancreat Sci* 2014;21:43–50.
- 30 Broome U, et al: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. *Gut* 1996;38:610–615.
- 31 Farrant J, et al: Natural history and prognostic variables in primary sclerosing cholangitis. *Gastroenterology* 1991;100:1710–1717.
- 32 Schrupf E, et al: Risk factors in primary sclerosing cholangitis. *J Hepatol* 1994;21:1061–1066.
- 33 Wiesner R, et al: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. *Hepatology* 1989;10:430–436.
- 34 Kaplan GG, et al: The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *Am J Gastroenterol* 2007;102:1042–1049.
- 35 Tanaka A, et al: Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. *Liver Int* 2008;28:983–989.
- 36 Escorsell A, et al: Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. *J Hepatol* 1994;21:787–791.
- 37 Berdal JE, Ebbesen J, Rydning A: Incidence and prevalence of autoimmune liver diseases (in Norwegian). *Tidsskr Nor Laegeforen* 1998;118:4517–4519.
- 38 Boberg KM, et al: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. *Scand J Gastroenterol* 1998;33:99–103.
- 39 Bambha K, et al: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. *Gastroenterology* 2003;125:1364–1369.
- 40 Card TR, Soleymani-Dodaran M, West J: Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. *J Hepatol* 2008;48:939–944.
- 41 Kingham JG, Kochar N, Gravenor MB: Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. *Gastroenterology* 2004;126:1929–1930.
- 42 Lindkvist B, et al: Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. *Hepatology* 2010;52:571–577.
- 43 Kaplan G, et al: The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *Am J Gastroenterol* 2007;102:1042–1049.
- 44 Boonstra K, et al: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. *Hepatology* 2013;58:2045–2055.
- 45 Tanaka A: The epidemiological study of PSC in Japan. Health Labour Sciences Research Grant from Research on Measures for Intractable Diseases, the Intractable Hepato-Biliary Disease Study Group in Japan (in Japanese). 2008.